=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1842

L1 SCREEN CREATED

=>
Uploading C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10510066.str





chain nodes :
12 13 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
14
chain bonds :
12-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 13-14

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS
Generic attributes :
12:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
16:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> s l3
SAMPLE SEARCH INITIATED 17:38:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 65237 TO ITERATE

3.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1289529 TO 1319951
PROJECTED ANSWERS: 310 TO 994

L4 1 SEA SSS SAM L2 AND L1

=> d l4 1

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 616870-29-2 REGISTRY
ED Entered STN: 14 Nov 2003
CN 6-Quinoxalinesulfonamide, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)
MF C34 H32 N6 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l3 sss full
FULL SEARCH INITIATED 17:38:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1304925 TO ITERATE

76.6% PROCESSED 1000000 ITERATIONS 474 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.14

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1304925 TO 1304925
PROJECTED ANSWERS: 544 TO 692

L5 474 SEA SSS FUL L2 AND L1

=> d l5 1 5 10

L5 ANSWER 1 OF 474 REGISTRY COPYRIGHT 2006 ACS on STN
RN 791631-99-7 REGISTRY
ED Entered STN: 02 Dec 2004
CN Benzamide, N-cyclopropyl-4-[3-[3-[6-[1-methyl-1-(methylsulfonyl)ethyl]-8-quinolinyl]phenyl]-2-quinoxalinyl]- (9CI) (CA INDEX NAME)
MF C37 H32 N4 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 5 OF 474 REGISTRY COPYRIGHT 2006 ACS on STN
RN 695816-05-8 REGISTRY
ED Entered STN: 20 Jun 2004
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)
MF C41 H45 N7 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 10 OF 474 REGISTRY COPYRIGHT 2006 ACS on STN
RN 616871-81-9 REGISTRY
ED Entered STN: 14 Nov 2003
CN 1H-Pyrazolo[3,4-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)
MF C34 H29 N7 . x C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 616871-80-8
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	175.86	176.07

FILE 'CAPLUS' ENTERED AT 17:39:37 ON 29 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L6 10 L5

=> d l6 1-10 bib abs fhitstr

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:133800 CAPLUS
DN 142:403601
TI Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members
AU DeFeo-Jones, Deborah; Barnett, Stanley F.; Fu, Sheng; Hancock, Paula J.; Haskell, Kathleen M.; Leander, Karen R.; McAvoy, Elizabeth; Robinson, Ronald G.; Duggan, Mark E.; Lindsley, Craig W.; Zhao, Zhijian; Huber, Hans E.; Jones, Raymond E.
CS Department of Cancer Research and Technology Enabled Synthesis Group, Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, USA
SO Molecular Cancer Therapeutics (2005), 4(2), 271-279
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal
LA English
AB Recent studies indicate that dysregulation of the Akt/PKB family of serine/threonine kinases is a prominent feature of many human cancers. The Akt/PKB family is composed of three members termed Akt1/PKBα, Akt2/PKB{szligbeta}, and Akt3/PKBγ. It is currently not known to what extent there is functional overlap between these family members. We have recently identified small mol. inhibitors of Akt. These compds. have pleckstrin homol. domain-dependent, isoenzyme-specific activity. In this report, we present data showing the relative contribution that inhibition of the different isoenzymes has on the apoptotic response of tumor cells to a variety of chemotherapies. In multiple cell backgrounds, maximal induction of caspase-3 activity is achieved when both Akt1 and Akt2 are inhibited. This induction is not reversed by overexpression of functionally active Akt3. The level of caspase-3 activation achieved under these conditions is equivalent to that observed with the phosphatidylinositol-3-kinase inhibitor LY294002. We also show that in different tumor cell backgrounds inhibition of mammalian target of rapamycin, a downstream substrate of Akt, is less effective in inducing caspase-3 activity than inhibition of Akt1 and Akt2. This shows that the survival phenotype conferred by Akt can be mediated by signaling pathways independent of mammalian target of rapamycin in some tumor cell backgrounds. Finally, we show that inhibition of both Akt1 and Akt2 selectively sensitizes tumor cells, but not normal cells, to apoptotic stimuli.
IT 612847-09-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKBs)
RN 612847-09-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:86368 CAPLUS
DN 142:211437
TI Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
AU Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.; Lindsley, Craig W.
CS Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 905-909
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:211437
AB This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compds. from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1.
IT 612848-44-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,3,5-trisubstituted pyridine derivs. as potent Akt1/Akt2 dual inhibitors)
RN 612848-44-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinolinyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:74699 CAPLUS
DN 142:211435

TI Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

AU Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; Robinson, Ronald G.; Barnett, Stanley F.; Defeo-Jones, Deborah; Jones, Raymond E.; Hartman, George D.; Huff, Joel R.; Huber, Hans E.; Duggan, Mark E.

CS Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, Merck & Co., West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 761-764
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 142:211435

AB This letter describes the development of two series of potent and selective allosteric Akt kinase inhibitors that display an unprecedented level of selectivity for either Akt1, Akt2 or both Akt1/Akt2. An iterative analog library synthesis approach quickly provided a highly selective Akt1/Akt2 inhibitor that induces apoptosis in tumor cells and inhibits Akt phosphorylation in vivo.

IT 612847-27-5P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(piperidinyl benzimidazolone derivs. preparation and SAR of Akt isoenzyme selective inhibition)

RN 612847-27-5 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965063 CAPLUS

DN 141:410960

TI Preparation of 8-(3-biaryl)phenylquinoline phosphodiesterase-4 inhibitors

IN Dube, Daniel; Dube, Laurence; Gallant, Michel; Lacombe, Patrick; Deschenes, Denis; MacDonald, Dwight

PA Merck Frosst Canada & Co., Can.

SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096220	A1	20041111	WO 2004-CA622	20040427

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

	AU 2004234190	A1	20041111	AU 2004-234190	20040427
	CA 2523336	AA	20041111	CA 2004-2523336	20040427
	EP 1635829	A1	20060322	EP 2004-729586	20040427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1812787	A	20060802	CN 2004-80018346	20040427
PRAI	US 2003-466542P	P	20030430		
	WO 2004-CA622	W	20040427		

OS MARPAT 141:410960
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title 8-phenylquinolines I [S1-S3 = H, OH, halo, alkyl, etc.; R1 = CO2aryl, CONHaryl, CONHheteroaryl, etc.; Ar1, Ar2 = (hetero)aryl or an N-oxide thereof; R2 = H, aryl, haloaryl, heterocyclyl, etc.; R3 = H, alkyl, hydroxyalkyl, etc.; R4 = H, halo, CN, alkyl, etc.] which are PDE4 inhibitors, were prepared E.g., a multi-step synthesis of II (no characterization data given for intermediates), which showed IC50 of 0.155 μM in LPS and FMLP-induced TNF-α and LTB4 assays in human whole blood, was given. The pharmaceutical compns. comprising the compound I are claimed.

IT 791631-99-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-(3-biaryl)phenylquinoline phosphodiesterase-4 inhibitors)

RN 791631-99-7 CAPLUS

CN Benzamide, N-cyclopropyl-4-[3-[3-[6-[1-methyl-1-(methylsulfonyl)ethyl]-8-quinolinyl]phenyl]-2-quinoxalinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:433750 CAPLUS
DN 141:7131
TI Preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for the treatment of cancer
IN Barnett, Stanley F.; Defeo-Jones, Deborah D.; Hartman, George D.; Huber, Hans E.; Stirdivant, Steven M.; Heimbrook, David C.
PA USA
SO U.S. Pat. Appl. Publ., 121 pp., which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004102360	A1	20040527	US 2003-678565	20031003
PRAI	US 2002-422312P	P	20021030		
	US 2003-460911P	P	20030407		

OS MARPAT 141:7131

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors I [wherein Q = (un)substituted heterocyclyl, aryl; U, V, W, and X = independently CH, N; Y, Z = independently CH, N, provided that at least one of Y and Z = N; n = 0-3; p = 0-2; q = 0-4; R1, R2, R7 = independently halo, CN, OH, CHO, NO2, or (un)substituted (cyclo)alkyl(oxy), alkenyl(oxy), alkynyl(oxy), heterocyclyl(oxy), acyl, carboxy, carbamoyl(oxy), ureido, sulfamoyl, etc.; R3, R4 = independently H, (perfluoro)alkyl; or CR3R4 = cycloalkyl, heterocyclyl; and pharmaceutically acceptable salts or stereoisomers thereof] or a combination of I and a protein kinase inhibitor II [wherein G = H2, O; X = C, N, SO0-2, O; m = 0-2; n = 0-2; p = 0-6; q = 0-4; R1 = independently H, halo, or (un)substituted (cyclo)alkyl, heterocyclyl, aryl, carbamoyl, amino, acyl, sulfamoyl, carboxy, etc.; R2 = H or (un)substituted (cyclo)alkyl(oxy), amino, aryloxy, heterocyclyloxy, alkenyloxy, alkynyloxy, etc.; R5 = independently H, halo, NO2, CN, or (un)substituted alkyl, alkenyl, alkynyl, carboxy, acyl, sulfamoyl, carbamoyl, ureido, amino, etc.; and pharmaceutically acceptable salts or stereoisomers thereof], optionally in combination with a third compound Examples include syntheses for I and II and assays demonstrating Akt inhibitor activity, antitumor activity, and the synergistic effect of combinations of AKT inhibitors and/or protein kinase inhibitors on caspase 3 activity. For instance, III•HCl was prepared in an 8-step reaction sequence culminating with the cycloaddn. of 4-(2-aminoprop-2-yl)benzil and o-phenylenediamine using glacial acetic acid in H2O, followed by work up with chloroform and ethanolic HCl. III•HCl, a selective Akt1 and Akt2 inhibitor, demonstrated a 3.2-fold in caspase 3 activation over control compared to a 1.2-fold increase for a protein kinase inhibitor. Combination treatment produced a 9-fold increase in caspase 3 activation.

IT 612847-29-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor agent; preparation of quinazolines and analogs as Akt inhibitors and indoles as protein kinase inhibitors for use in synergistic combination therapy for treatment of cancer)

RN 612847-29-7 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:836857 CAPLUS

DN 139:350755
TI Preparation of fused quinoxaline derivatives as inhibitors of Akt activity for treating cancer
IN Lindsley, Craig W.; Zhao, Zhijian
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086404	A1	20031023	WO 2003-US10447	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481241	AA	20031023	CA 2003-2481241	20030404
	AU 2003226271	A1	20031027	AU 2003-226271	20030404
	EP 1494676	A1	20050112	EP 2003-746610	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005159422	A1	20050721	US 2003-510066	20030404
	JP 2005528394	T2	20050922	JP 2003-583423	20030404
PRAI	US 2002-370833P	P	20020408		
	US 2002-417411P	P	20021009		
	WO 2003-US10447	W	20030404		

OS MARPAT 139:350755
GI



I



II

AB The title compds. [I; u, v and x = CH, N; w = a bond, CH, N; y, z = CH, N (provided that at least one of y and z = N); R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl; or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5, R6 = H, aryl, heterocyclyl, etc.; or NR5R6 = monocyclic or bicyclic heterocycle; n = 0-2; p = 0-3; t = 2-6; m = 0-2] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared Thus, alkylating 4-(keto-1-benzimidazolinyl)piperidine with 4-bromomethylbenzil followed by condensing the resulting intermediate with 5,6-diaminobenzimidazole.3HCl afforded the imidazoquinoxaline II. Specific compds. I were found to have IC50 of ≤ 20 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.

IT 612847-09-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused quinoxaline derivs. as inhibitors of Akt activity for treating cancer)

RN 612847-09-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:836856 CAPLUS
DN 139:337991
TI Preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity
IN Lindsley, Craig W.; Zhao, Zhijian
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086403	A1	20031023	WO 2003-US10341	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480880	AA	20031023	CA 2003-2480880	20030404
	AU 2003230802	A1	20031027	AU 2003-230802	20030404
	EP 1496906	A1	20050119	EP 2003-723899	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005130977	A1	20050616	US 2003-510067	20030404
	JP 2005530726	T2	20051013	JP 2003-583422	20030404
PRAI	US 2002-370846P	P	20020408		
	WO 2003-US10341	W	20030404		

OS MARPAT 139:337991
GI



I

AB The title compds. comprising a 2,3-diphenylquinoxaline moiety [I; u, v, w and x = CH, N; y, z = CH, N (provided that at least one of y and z = N); R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl; or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5 = H, aryl, heterocyclyl, etc.; R6 = (un)substituted NH2, alkyl, perfluoroalkyl, etc.; n = 0-3; p = 0-2; t = 2-6; m = 0-2] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared E.g., a 3-step synthesis of N-[4-(3-phenylquinoxalin-2-yl)benzyl] propanesulfonamide (starting from 4-bromomethylbenzil and 1,2-diaminobenzene), was given. The exemplified compds. I were found to have IC50 of ≤ 50 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.

IT 616224-02-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[4-(3-phenylquinoxalin-2-yl)benzyl] substituted sulfonamides as inhibitors of Akt activity for treating cancer)

RN 616224-02-3 CAPLUS

CN Benzenesulfonamide, N-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:836848 CAPLUS
DN 139:350754

TI Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer

IN Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.; Manley, Peter J.; Wu, Zhicai; Zhao, Zhijian

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086394	A1	20031023	WO 2003-US10442	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480800	AA	20031023	CA 2003-2480800	20030404
	AU 2003223467	A1	20031027	AU 2003-223467	20030404
	EP 1496896	A1	20050119	EP 2003-719597	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533010	T2	20051104	JP 2003-583413	20030404
	US 2005222155	A1	20051006	US 2004-510069	20041004
PRAI	US 2002-370847P	P	20020408		
	US 2002-417174P	P	20021009		
	WO 2003-US10442	W	20030404		

OS MARPAT 139:350754

GI



I



II

AB The title compds. comprising a 2,3-diphenylquinoxaline moiety [I; u, v, w and x = CH, N; y, z = CH, N (provided that at least one of y and z = N); Q = NR5R6, (un)substituted aryl, heterocyclyl; R1 = alkenyl, halo, CN, etc.; R2 = OH, CN, CO2H, etc.; R3, R4 = H, alkyl, perfluoroalkyl; or R3 and R4 are combined to form (CH2)t wherein one of the carbon atoms is optionally replaced by O, SOm, (un)substituted NHCO, N(COH); R5, R6 = H, aryl, heterocyclyl, etc.; or NR5R6 = monocyclic or bicyclic heterocycle; R7 = halo, CN, CO2H, etc.; n = 0-3; p = 0-2; t = 2-6; m = 0-2; q = 0-4; r = 0-1] and their salts which inhibit the activity of Akt, a serine/threonine protein kinase, were prepared E.g., a 2-step synthesis of the quinoxaline II [starting from 4-bromomethylbenzil and 4-(2-keto-1-benzimidazolinyl)piperidine], was given. The exemplified compds. I were found to have IC50 of ≤ 50 μM against one or more of Akt1, Akt2 and Akt3. The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for treating cancer comprising administration of the compds. I.

IT 612847-29-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2,3-diphenylquinoxaline derivs. as inhibitors of Akt activity for treating cancer)

RN 612847-29-7 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:818232 CAPLUS
DN 139:323527
TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer
IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber, Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman, George D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226301	A1	20031020	AU 2003-226301	20030404
	US 2006142178	A1	20060629	US 2004-510068	20041004
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
	WO 2003-US10632	W	20030404		

GI



I



II

AB Triazolo[4,3-b]pyridazines I [R1 = (un)substituted Ph, furyl, thienyl, pyridinyl; R2 = substituted NH2, OH; R3 = H, R4 = (un)substituted cycloalkyl, aryl; R3R4 = (un)substituted CH:CHCH:CH] and quinazolines II [R5, R6 = (un)substituted Ph; R7 = H, alkyl, halogen, OH, alkoxy] were prepared for use as inhibitors of one or two of the isoforms of Akt, a serine/threonine protein kinase, acting particularly on the pleckstrin homol. domain of Akt. Thus, 3,6-dichloropyridazine was converted to its 4-cyclobutyl derivative which was cyclized with BzNHNH2 and aminated to give I [R1 = Ph, R2 = NHCH2CMe2CH2NMe2, R3 = H, R4 = cyclobutyl]. This compound had IC50 for inhibition of Akt1 of 1.4 μM.

IT 612847-30-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)

RN 612847-30-0 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-29-7
CMF C34 H29 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:517279 CAPLUS
DN 119:117279
TI A process for the preparation of thieno[4,5-g] quinoxaline amebicides
IN Venugopalan, Bindumadhavan; Bapat, Chintamani Prabhakar; Chatterjee, Deepak Kumar; De Souza, Noel John; Rupp, Richard Helmut
PA Hoechst India Ltd., India

SO Indian, 26 pp.
CODEN: INXXAP
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 167425	A	19901027	IN 1988-BO46	19880226
PRAI IN 1988-BO46		19880226		

OS MARPAT 119:117279
GI



I



II

AB The title compds. I [R = OH, alkoxy, XYN; X, Y = H, alkyl, alkenyl, hydroxyalkyl, (dialkylamino)alkyl; when X = H then Y = (un)substituted alkyl, aryl, arylalkyl, heterocycle; R1, R2 = X, Y; XY = cyclic substituent], useful as amebicides (no data), are prepared by reacting thienoquinoxalines II (R3 = C1-6 alkyl; Z = halogen) with HNR1R2 in a solvent (e.g., DMF, dioxane, THF) at 27-110° to effect an amine condensation, hydrolyzing the ester with aqueous alkali, reacting with SOCl2, and amidating the acid chloride with amine HNXY. Thus, in this manner, I [R = NEt2, R1R2 = (CH2)5] was prepared having m.p. 80-81°.

IT 149397-04-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and amebicidal activity of)

RN 149397-04-6 CAPLUS

CN Thieno[2,3-g]quinoxaline-7-carboxylic acid, 2,3-bis[4-[(hexahydro-1(2H)-azocinyl)methyl]phenyl]-5,9-dimethoxy-8-methyl-, methyl ester (9CI) (CA INDEX NAME)



=> d l6 6 9 bib hitstr

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:836857 CAPLUS
DN 139:350755
TI Preparation of fused quinoxaline derivatives as inhibitors of Akt activity for treating cancer
IN Lindsley, Craig W.; Zhao, Zhijian
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086404	A1	20031023	WO 2003-US10447	20030404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481241	AA	20031023	CA 2003-2481241	20030404
	AU 2003226271	A1	20031027	AU 2003-226271	20030404
	EP 1494676	A1	20050112	EP 2003-746610	20030404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005159422	A1	20050721	US 2003-510066	20030404
	JP 2005528394	T2	20050922	JP 2003-583423	20030404
PRAI	US 2002-370833P	P	20020408		
	US 2002-417411P	P	20021009		
	WO 2003-US10447	W	20030404		

OS MARPAT 139:350755
IT 612847-09-3P 612847-10-6P 612847-11-7P
612847-12-8P 612847-13-9P 612847-14-0P
612848-66-5P 612848-67-6P 612848-68-7P

612848-69-8P 612848-70-1P 612848-71-2P
612848-72-3P 612848-73-4P 616871-66-0P
616871-67-1P 616871-68-2P 616871-69-3P
616871-70-6P 616871-71-7P 616871-72-8P
616871-73-9P 616871-74-0P 616871-75-1P
616871-76-2P 616871-77-3P 616871-78-4P
616871-79-5P 616871-80-8P 616871-81-9P
616871-82-0P 616871-83-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused quinoxaline derivs. as inhibitors of Akt activity for treating cancer)

RN 612847-09-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612847-10-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-09-3
CMF C34 H29 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-11-7 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 612847-12-8 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-11-7
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-13-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]quinoxaline, 7-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 612847-14-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]quinoxaline, 7-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-13-9
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-66-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612848-67-6 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5
CMF C30 H25 N7 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-68-7 CAPLUS
CN Carbamic acid, [1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 612848-69-8 CAPLUS
CN Carbamic acid, [1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-azetidinyl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-68-7
CMF C30 H30 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-70-1 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 612848-71-2 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-70-1
CMF C32 H28 N10



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-72-3 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 612848-73-4 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-

piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-72-3
CMF C33 H28 N8



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-66-0 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)- (9CI) (CA INDEX NAME)



RN 616871-67-1 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-66-0
CMF C24 H21 N5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-68-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenylbenzo[g]quinoxalin-2-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616871-69-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenylbenzo[g]quinoxalin-2-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-68-2
CMF C37 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 616871-70-6 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(7-phenyl-1H-pyrazolo[3,4-g]quinoxalin-6-yl)- (9CI) (CA INDEX NAME)



RN 616871-71-7 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(7-phenyl-1H-pyrazolo[3,4-g]quinoxalin-6-yl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-70-6
CMF C24 H21 N5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-72-8 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(6-phenyl-1H-pyrazolo[3,4-g]quinoxalin-7-yl)- (9CI) (CA INDEX NAME)



RN 616871-73-9 CAPLUS
CN Benzenemethanamine, N,N-dimethyl-4-(6-phenyl-1H-pyrazolo[3,4-g]quinoxalin-7-yl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-72-8
CMF C24 H21 N5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-74-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-pyrazolo[3,4-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616871-75-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-pyrazolo[3,4-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI)

(CA INDEX NAME)

CM 1

CRN 616871-74-0
CMF C34 H29 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-76-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-pyrazolo[3,4-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616871-77-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-pyrazolo[3,4-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-76-2
CMF C34 H29 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-78-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-1,2,3-triazolo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 616871-79-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-1,2,3-triazolo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-78-4
CMF C33 H28 N8 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-80-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl- (9CI) (CA INDEX NAME)



RN 616871-81-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-80-8
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 616871-82-0 CAPLUS
CN 2H-Imidazo[4,5-g]quinoxalin-2-one, 6-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-1,3-dihydro-7-phenyl- (9CI) (CA INDEX NAME)



RN 616871-83-1 CAPLUS
CN 2H-Imidazo[4,5-g]quinoxalin-2-one, 6-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-1,3-dihydro-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 616871-82-0
CMF C34 H29 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:818232 CAPLUS
DN 139:323527
TI Preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer
IN Barnett, Stanley F.; Defeo-Jones, Deborah; Haskell, Kathleen M.; Huber, Hans E.; Nahas, Deborah D.; Lindsley, Craig W.; Zhao, Zhijian; Hartman, George D.

PA Merck & Co., Inc., USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084473	A2	20031016	WO 2003-US10632	20030404
	WO 2003084473	A3	20040212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226301	A1	20031020	AU 2003-226301	20030404
	US 2006142178	A1	20060629	US 2004-510068	20041004
PRAI	US 2002-370827P	P	20020408		
	US 2002-417202P	P	20021009		
	WO 2003-US10632	W	20030404		

IT 612847-30-0P 612847-32-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)
RN 612847-30-0 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-29-7
CMF C34 H29 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-32-2 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-31-1
CMF C34 H29 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 612847-10-6P 612847-12-8P 612847-14-0P
612847-28-6P 612847-34-4P 612847-41-3P
612847-42-4P 612847-43-5P 612847-45-7P
612847-47-9P 612847-49-1P 612847-51-5P
612847-53-7P 612847-55-9P 612847-57-1P
612847-59-3P 612847-61-7P 612847-63-9P
612847-65-1P 612847-67-3P 612847-69-5P
612847-71-9P 612847-73-1P 612847-75-3P
612847-77-5P 612847-79-7P 612847-85-5P
612847-87-7P 612847-89-9P 612847-97-9P
612847-99-1P 612848-01-8P 612848-03-0P
612848-05-2P 612848-07-4P 612848-09-6P
612848-11-0P 612848-13-2P 612848-15-4P
612848-17-6P 612848-19-8P 612848-21-2P
612848-23-4P 612848-31-4P 612848-33-6P
612848-35-8P 612848-37-0P 612848-39-2P
612848-41-6P 612848-45-0P 612848-47-2P

612848-49-4P 612848-51-8P 612848-56-3P
612848-57-4P 612848-59-6P 612848-61-0P
612848-63-2P 612848-65-4P 612848-67-6P
612848-69-8P 612848-71-2P 612848-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)

RN 612847-10-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-09-3
CMF C34 H29 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-12-8 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-11-7
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-14-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]quinoxaline, 7-[4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]methyl]phenyl]-6-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-13-9
CMF C34 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-28-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-

quinoxalinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-27-5
CMF C33 H29 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-34-4 CAPLUS
CN 6-Quinoxalinecarboxamide, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-phenyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-33-3
CMF C40 H38 N8 O2

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-41-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-40-2
CMF C34 H29 N9 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-42-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 612847-43-5 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 612847-45-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-(6,7-diamino-3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-44-6
CMF C33 H31 N7 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-47-9 CAPLUS
CN Quinoxaline, 2-[4-[[3-(1H-indol-3-yl)-1-pyrrolidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-46-8
CMF C33 H28 N4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-49-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[3-(2-aminophenyl)-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-48-0
CMF C33 H30 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-51-5 CAPLUS
CN Benzamide, 3,4-dichloro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-50-4
CMF C32 H26 Cl2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-53-7 CAPLUS
CN Benzamide, 4-cyano-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-52-6
CMF C33 H27 N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-55-9 CAPLUS
CN Benzamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-3-(trifluoromethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-54-8
CMF C33 H27 F3 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-57-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-56-0
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-59-3 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-58-2
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-61-7 CAPLUS
CN Benzamide, 3,5-difluoro-N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-60-6
CMF C32 H26 F2 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-63-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-62-8
CMF C29 H25 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-65-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-64-0
CMF C29 H25 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-67-3 CAPLUS
CN 4-Thiazolidinecarboxamide, N-[(3R)-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-66-2
CMF C29 H29 N5 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-69-5 CAPLUS
CN 1H-Pyrazol-5-amine, 1,3-dimethyl-4-[1,2,3,6-tetrahydro-1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-pyridinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-68-4
CMF C31 H30 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 612847-71-9 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(5-amino-1,3-dimethyl-1H-pyrazol-4-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-70-8
CMF C31 H31 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-73-1 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(5-amino-1,3-dimethyl-1H-pyrazol-4-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-72-0
CMF C31 H31 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-75-3 CAPLUS
CN 1H-Pyrazol-5-amine, 4-[1-[[4-(6-chloro-3-phenyl-2-quinoxalinyl)phenyl]methyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-74-2
CMF C31 H29 Cl N6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-77-5 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(5-amino-1,3-dimethyl-1H-pyrazol-4-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]phenyl]-3-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-76-4
CMF C32 H30 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-79-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(5-amino-1,3-dimethyl-1H-pyrazol-4-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl]phenyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-78-6
CMF C32 H30 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-85-5 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(7-amino-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-84-4
CMF C29 H26 N6 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-87-7 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-phenyl-2-[4-[[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-86-6
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-89-9 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-phenyl-3-[4-[[(3R)-3-[(5-thiazolylcarbonyl)amino]-1-pyrrolidinyl]methyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-88-8
CMF C30 H25 N5 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-97-9 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(5-hydroxy-3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612847-96-8
CMF C29 H25 N5 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612847-99-1 CAPLUS
CN Urea, N-(3-methylphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-98-0
CMF C32 H29 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-01-8 CAPLUS
CN Urea, N-(4-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-00-7
CMF C32 H29 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-03-0 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-02-9
CMF C32 H29 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-05-2 CAPLUS
CN Benzoic acid, 3-[[[[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-azetidinyl]amino]carbonyl]amino]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-04-1
CMF C33 H29 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-07-4 CAPLUS
CN Urea, N-[4-(difluoromethoxy)phenyl]-N'-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-3-azetidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-06-3
CMF C32 H27 F2 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-09-6 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-08-5
CMF C34 H31 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-11-0 CAPLUS
CN Acetamide, N-[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxalinyl]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-10-9
CMF C37 H37 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-13-2 CAPLUS
CN Acetamide, N-[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxalinyl]-2-(dimethylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-12-1
CMF C37 H37 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-15-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-14-3
CMF C31 H28 N8



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-17-6 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-16-5
CMF C31 H29 N9



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-19-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-chloro-3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-18-7
CMF C31 H27 Cl N8



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-21-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-20-1
CMF C31 H29 N9



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-23-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(7-chloro-3-phenyl-2-quinoxalinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-22-3
CMF C31 H27 Cl N8



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-31-4 CAPLUS
CN 5-Quinoxalinol, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-30-3
CMF C31 H28 N8 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-33-6 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-32-5
CMF C32 H28 N8 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-35-8 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 3-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-34-7
CMF C32 H28 N8 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-37-0 CAPLUS
CN Quinoxaline, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-36-9
CMF C32 H28 N6



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-39-2 CAPLUS
CN 6-Quinoxalinamine, 2-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-38-1
CMF C32 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-41-6 CAPLUS
CN 6-Quinoxalinamine, 3-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-40-5
CMF C32 H29 N7



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-45-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(3-phenyl-2-quinolinyl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-44-9
CMF C34 H30 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-47-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-46-1
CMF C34 H29 N9 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-49-4 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[3-phenyl-7-(1H-tetrazol-5-yl)-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-48-3
CMF C32 H28 N12



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-51-8 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-[3-phenyl-6-(1H-tetrazol-5-yl)-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-50-7
CMF C32 H28 N12



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-56-3 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-43-5
CMF C40 H43 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-57-4 CAPLUS
CN 6-Quinoxalinecarboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612847-42-4
CMF C40 H43 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-59-6 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl-6-quinoxalinyl]carbonyl]amino]-, (2ξ)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-58-5
CMF C40 H40 N6 O7

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-61-0 CAPLUS
CN D-arabino-Hexose, 2-deoxy-2-[[[3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl-6-quinoxalinyl]carbonyl]amino]-, (2ξ)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-60-9
CMF C40 H40 N6 O7

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-63-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-62-1
CMF C41 H42 N6 O7

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-65-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[[4-[7-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]oxy]-3-phenyl-2-quinoxalinyl]phenyl]methyl]-4-piperidinyl]-1,3-dihydro-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612848-64-3
CMF C41 H42 N6 O7

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-67-6 CAPLUS
CN 5-Thiazolecarboxamide, N-[(3R)-1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-pyrrolidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-66-5
CMF C30 H25 N7 O S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-69-8 CAPLUS
CN Carbamic acid, [1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-3-azetidinyl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-68-7
CMF C30 H30 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-71-2 CAPLUS
CN 9H-Purin-6-amine, 9-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-70-1
CMF C32 H28 N10



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612848-73-4 CAPLUS
CN 1H-Imidazo[4,5-g]quinoxaline, 6-[4-[[4-(3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]methyl]phenyl]-7-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612848-72-3
CMF C33 H28 N8



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 612848-75-6P 612848-76-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of triazolo[4,3-b]pyridazines and 2,3-diarylquinazolines for the treatment of cancer)
RN 612848-75-6 CAPLUS
CN 6-Quinoxalinecarbonitrile, 3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 612848-76-7 CAPLUS
CN 6-Quinoxalinecarbonitrile, 2-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



=> file caold
COST IN U.S. DOLLARS SINCE FILE TOTAL